Screener
Syndax Pharmaceuticals SNDX Q2 2026 earnings
Reported August 4, 2026 · After market close
Revenue$72.8MMiss by $6.6M
EPS-$0.55Miss by $0.10
Revenue estimate$79.4M
EPS estimate-$0.45
“We delivered another quarter of strong commercial results, with both our medicines now annualizing at well over $200 million each and positioned for further growth. Notably, we achieved $55 million in Revuforj net revenue and the sixth consecutive quarter of double-digit net revenue and prescription growth, highlighting our leadership in menin inhibition, robust demand in both NPM1 and KMT2A, and an increasing average treatment duration. Niktimvo net revenue grew to $60 million this quarter, underscoring the benefits of its unique mechanism of action in cGVHD and the substantial commercial opportunity.”
Next report
Nov 2, 2026 (in a month)Revenue estimate$82.8M
EPS estimate-$0.51
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Syndax Pharmaceuticals report Q2 2026 earnings?
- Syndax Pharmaceuticals (SNDX) reported Q2 2026 earnings on August 4, 2026 after market close.
- What were Syndax Pharmaceuticals's Q2 2026 revenue and EPS?
- Syndax Pharmaceuticals reported revenue of $72.8M and eps of $-0.55 for Q2 2026.
- Did Syndax Pharmaceuticals beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $79.4M by $6.6M. EPS missed the consensus estimate of $-0.45 by $0.10.
- How did Syndax Pharmaceuticals's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 91.8% from $38.0M a year earlier and eps grew 33.7% from $-0.83.
- Where can I find Syndax Pharmaceuticals's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-332736) and the 10-Q periodic report (0001193125-26-332750) directly on SEC EDGAR. The filing index links above go to sec.gov.
